[Featured Stock] IMBDX, 'The Second 20 Trillion Natera'... 8x More Accurate Cancer Recurrence Detection with Video Inspection

IMBDX is showing strong performance. The news that it has submitted an application for innovative medical technology review for CancerDetect, the first domestic product for detecting cancer recurrence after surgery, appears to be influencing its stock price. The company explained that Natera, a global competitor in the field of minimal residual disease (MRD) recurrence detection based in the United States, reported a 58% year-over-year growth in Q2 earnings this year. The number of tests also increased by about 50% compared to the same period last year, reaching 125,000 tests. IMBDX expects that CancerDetect will be fully recognized in the market for its value once it is clinically applied after the completion of the innovative medical technology review. Since the beginning of this year, Natera’s market capitalization has exceeded 20 trillion KRW.

As of 9:24 AM on the 20th, IMBDX was trading at 21,800 KRW, up 3,110 KRW (16.64%) from the previous trading day.

IMBDX is a precision medicine company that analyzes genes in the blood to diagnose cancer early and provide personalized cancer treatment guidance. On this day, the company announced that it had submitted an application for innovative medical technology review for CancerDetect, a test product that can detect cancer recurrence as early as three weeks after surgery.

Innovative medical technology is a system under the new medical technology evaluation project, which allows early clinical use of new technological products if their safety and potential are recognized, according to standards set by the Minister of Health and Welfare.

IMBDX’s CancerDetect is a product that detects minimal residual disease (MRD) remaining after cancer surgery, enabling early confirmation of cancer recurrence to help achieve complete cure and ultimately improve patient survival rates. CancerDetect detects unique genetic mutations imprinted on a patient’s cancer cells from the blood, possessing world-class accuracy capable of detecting mutations even at a very low rate of 0.001%.

Kim Tae-yu, CEO of IMBDX, explained, “If CancerDetect is introduced to the medical field as the first domestic product, it can proactively classify surgical patients according to their risk of recurrence, reducing unnecessary chemotherapy for patients with low recurrence risk.” He added, “For patients in whom minimal residual disease is detected, early aggressive chemotherapy is recommended to manage recurrence risk, which is expected to reduce cancer-related mortality across society and decrease social costs spent on unnecessary chemotherapy.”

Heo Seon-jae, a researcher at SK Securities, said, “IMBDX plans to begin penetrating the cancer recurrence monitoring and chemotherapy market, where unmet medical needs are significant, through CancerDetect, the only domestic cancer recurrence detection platform.” He explained, “With a high cancer recurrence probability of around 30%, CancerDetect can effectively complement the limitations of existing imaging tests through personalized gene panel testing.” CancerDetect has improved accuracy by eight times compared to imaging tests.

Researcher Heo added, “With the submission for new medical technology evaluation, full-scale product commercialization work will begin,” and noted, “The leading company in the cancer recurrence detection market is Natera, listed on the U.S. Nasdaq.”